Nafamostat Efficacy in Phase 3 Registrational CRRT Study
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Acute Kidney Injury
In brief
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.
Key facts
- Study ID
- NCT06150742
- Run by
- Talphera, Inc
- People needed
- 70
- Starts
- 2024-08-15
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2025-10-15
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients requiring CRRT or undergoing CRRT initiated within the prior 48 hours
- Patients who cannot tolerate heparin or are at high risk of bleeding
You may not qualify if…
- Patients weighing less than 50 kg
- Patients receiving systemic anticoagulation
- Patients with active bleeding
Where it is running
- Baylor University Medical Center — Dallas, Texas, United States (enrolling)
- University of California Los Angeles — Los Angeles, California, United States (enrolling)
- Henry Ford Health — Detroit, Michigan, United States (enrolling)
- University of New Mexico — Albuquerque, New Mexico, United States (enrolling)
- Northwell Health — Great Neck, New York, United States (enrolling)
- Mount Sinai — New York, New York, United States (enrolling)
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (enrolling)
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States (enrolling)
- Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
- AdventHealth — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.